The recently approved weight-loss pill Wegovy is drawing significant interest, particularly among older men, due to its discretion and ease of use compared to the injectable version of the medication, according to pharmacy sources. Manufactured by Novo Nordisk and authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) last month, Wegovy became available in private and high-street pharmacies approximately three weeks ago.

Data from online retailers and independent pharmacies indicate a marked shift in patient preference. CheqUp, an online pharmacy, reported a 350 percent increase in demand for the pill since its launch two weeks ago. Approximately two-thirds of their patients transitioning to the pill had previously been using the injectable form. Lisa Tookey, chief executive of CheqUp, noted that although it is early for definitive conclusions, the initial uptake suggests strong consumer interest in an oral alternative to injections.

The Family Chemist, an independent online pharmacy, has prescribed Wegovy to about 1,000 new patients since the product became available. Sunny Dhain, the pharmacy’s clinical director, highlighted that while obesity rates tend to be higher in men, women traditionally comprised the majority of patients seeking weight-loss injections. However, since the introduction of the pill, there has been an increase in male patients, particularly those over 40.

Dhain explained that the oral administration of Wegovy offers greater privacy, as it eliminates the need to store injections in refrigeration or schedule doses around social activities. This discretion appears to be a significant factor driving interest among men who prefer to keep their weight management efforts private. “Healthcare is personal, and many patients simply value having the choice to keep treatment private," Dhain said, noting that both openness and privacy about treatment are valid approaches.

Research conducted by Pharmacy2U revealed behavioural trends among patients on weight-loss medications, with around half willing to alter dosing schedules without consulting a medical professional. The survey found that 27 percent overall, and as many as 41 percent of those under 35, might share their medication with family or friends. The tendency to share was reported by 33 percent of men and 20 percent of women in their patient cohort.

The uptake of Wegovy and shifting patient preferences illustrate evolving attitudes toward weight management treatments. While injectable options have been the standard, the appeal of a daily pill that can be integrated discreetly is influencing more men, especially older adults, to seek pharmaceutical assistance for obesity. The initial data implies a growing market for oral GLP-1 receptor agonists, though it remains early to assess the long-term impact on demand and treatment patterns.